通过抑制血小板聚合和血栓 (FIIa) /激活X因子 (FXa) 活性来抑制3-deoxysappanchalcone的抗血栓活性
Gyuri Han1, Jinhee Lee1, Jong-Sup Bae1
1Research Institute of Pharmaceutical Sciences, CMRI, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
Molecules (Basel, Switzerland)
|June 27, 2025
概括
来自Caesalpinia sappan的3-deoxysappanchalcone (3-DSC) 显示出显著的抗血栓作用. 这种植物化合物有效地抑制血栓形成和凝血通路,表明它有可能成为一种新型抗凝剂.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
- 血管生物学 血管生物学
背景情况:
- 植物衍生化合物被探索为血管健康治疗.
- 来自Caesalpinia sappan的3-deoxysappanchalcone (3-DSC) 已知具有抗炎和抗过敏的作用.
- 目前,3-DSC的抗血栓和静血潜力尚未得到研究.
研究的目的:
- 为了评估3-DSC的抗血栓潜力.
- 评估3-DSC对凝血和纤维解析途径的影响.
- 为了研究3-DSC作为抗凝剂的治疗潜力.
主要方法:
- 在体外测定:激活的部分血栓形成时间 (aPTT),前热血素时间 (PT),血栓 (FIIa) 和XA因子 (FXa) 活性,纤维素聚合和血小板聚合.
- 在小鼠体内研究以评估抗血栓性作用.
- 在TNF-α刺激的HUVEC中评估1型血原激活剂抑制剂 (PAI-1) 和组织型血原激活剂 (t-PA) 表达.
主要成果:
- 3-DSC延长了aPTT和PT,抑制了血栓和FXa的活性和产生.
- 3-DSC抑制了由血栓激发的纤维素聚合和血小板聚合.
- 3-DSC在体内表现出抗凝剂作用,并降低了PAI-1/t-PA比率.
结论:
- 3-DSC具有显著的抗血栓性质.
- 该化合物调节关键的凝血和纤维素分解通路.
- 3-DSC在开发新的抗凝固疗法方面表现有前途.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
653
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
653
Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Formation of the Platelet Plug
7.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.2K
Venous Thrombosis III: Interprofessional Care
27
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
27


